Laterally Extended Endopelvic Resection Versus Chemo or Targeted Therapy Alone for Pelvic Sidewall Recurrence of Cervical Cancer

Soo Jin Park †, Jaehee Mun †, Seungmee Lee 2, Yanlin Luo 3, Hyun Hoon Chung 1, Jae-Weon Kim 1, Noh Hyun Park 1, Yong Sang Song 1† and Hee Seung Kim 1*† and on behalf of the FUSION study group

1 Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea, 2 Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, South Korea, 3 Department of Gynecologic Oncology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China

Background: Laterally extended endopelvic resection (LEER) has been introduced for treatment of pelvic sidewall recurrence of cervical cancer (PSRCC), which occurs in only 8% of patients with relapsed cervical cancer. LEER can only be performed by a proficient surgeon due to the high risk of surgical morbidity and mortality, but there is no evidence as to whether LEER is may be more effective than chemo or targeted therapy alone for PSRCC. Thus, we aimed to compare the efficacy and safety between LEER and chemo or targeted therapy alone for treatment of PSRCC.

Methods: We prospectively recruited patients with PSRCC who underwent LEER between December 2016 and December 2019. Moreover, we retrospectively collected data on patients with PSRCC who received chemo or targeted therapy alone between January 2000 and December 2019. We compared treatment-free interval (TFI), progression-free survival (PFS), treatment-free survival (TFS), overall survival (OS), tumor response, neurologic disturbance of the low extremities, and pelvic pain severity in the different patient groups.

Results: Among 1295 patients with cervical cancer, we included 28 (2.2%) and 31 (2.4%) in the prospective and retrospective cohorts, respectively. When we subdivided all patients into two groups based on the median value of prior TFI (PTFI, 9.2 months), LEER improved TFI, PFS, TRS and OS compared to chemo or targeted therapy alone (median, 2.8 vs. 0.9; 7.4 vs. 4.1; 30.1 vs. 16.9 months; P ≤ 0.05) in patients with PTFI < 9.2 months despite no difference in survival in those with PTFI ≥ 9.2 months, suggesting that LEER may lead to better TFI, PFS, TRS and OS in patients with PTFI < 9.2 months (adjusted hazard ratios, 0.28, 0.27, 0.44 and 0.37; 95% confidence intervals, 0.12-0.68, 0.11-0.66, 0.18-0.83 and 0.15-0.88). Furthermore, LEER markedly reduced the number
Postoperative complications and quality of life compared to chemo or targeted therapy alone for patients with isolated vaginal recurrence with acceptable pelvic sidewall recurrence of cervical cancer, which is seen in 10.7% of patients with disease recurrence after radical treatment such as radiotherapy and radical hysterectomy. Vaginectomy provides another option for patients with isolated vaginal recurrence with acceptable postoperative complications and quality of life compared to radiotherapy or pelvic exenteration (1, 2). The five-year survival rate of such patients ranges from 30 to 60% (3). On the other hand, pelvic sidewall recurrence of cervical cancer (PSRCC) is relatively rare, occurring in 8.3% of patients with disease recurrence (4). However, tumors invading the pelvic sidewall structure are not easy to remove by pelvic exenteration, and residual tumors after pelvic exenteration are associated with poor prognosis (5, 6). Since salvage radiotherapy reportedly fails to treat loco-regional tumors in a previously irradiated field, palliative chemotherapy is mainly used to slow disease progression and control the pelvic pain caused by tumor invasion in the pelvic sidewall structure (3, 4).

Laterally extended endopelvic resection (LEER), an ultra-radical surgery that aims to remove pelvic sidewall tumors, has been used since 1999 in an effort to improve patient survival (7). Based on the ontogenetic compartment theory, LEER can provide tumor-free margins (R0) by resecting tumors that propagate through multi-compartmental borders between the pelvic floor and sidewall muscles and the internal iliac vessel system (8). However, LEER is a highly skilled surgery that can only be done by a proficient surgeon. It requires definite anatomical knowledge of pelvic sidewall structure due to the risk of massive bleeding during resection of tumors invading the major pelvic vessels, and adhesion and fibrosis in a previously debulked or irradiated pelvis can increase surgical morbidity and mortality (9, 10).

Despite these limitations, LEER reportedly produces a five-year survival rate of about 50%, and the number of studies on the feasibility of LEER for selected patients with PSRCC has gradually been increasing since 2015 (6, 9–14). However, the criteria for identification of patients for whom LEER may be beneficial remain ambiguous, and there is no evidence as to whether LEER may be more effective than palliative chemo or targeted therapy alone. This is an especially important question considering the high number of morbidities related to LEER. Thus, we performed a prospective cohort study to evaluate the efficacy and safety of LEER for patients with PSRCC and investigated the criteria for selection of patients who may benefit from LEER compared to chemo or targeted therapy alone.

**INTRODUCTION**

Pelvic exenteration can be attempted as a cure for central recurrence of cervical cancer, which is seen in 10.7% of patients with disease recurrence after radical treatment such as radiotherapy and radical hysterectomy. Vaginectomy provides another option for patients with isolated vaginal recurrence with acceptable postoperative complications and quality of life compared to radiotherapy or pelvic exenteration (1, 2). The five-year survival rate of such patients ranges from 30 to 60% (3). On the other hand, pelvic sidewall recurrence of cervical cancer (PSRCC) is relatively rare, occurring in 8.3% of patients with disease recurrence (4). However, tumors invading the pelvic sidewall structure are not easy to remove by pelvic exenteration, and residual tumors after pelvic exenteration are associated with poor prognosis (5, 6). Since salvage radiotherapy reportedly fails to treat loco-regional tumors in a previously irradiated field, palliative chemotherapy is mainly used to slow disease progression and control the pelvic pain caused by tumor invasion in the pelvic sidewall structure (3, 4).

Laterally extended endopelvic resection (LEER), an ultra-radical surgery that aims to remove pelvic sidewall tumors, has been used since 1999 in an effort to improve patient survival (7). Based on the ontogenetic compartment theory, LEER can provide tumor-free margins (R0) by resecting tumors that propagate through multi-compartmental borders between the pelvic floor and sidewall muscles and the internal iliac vessel system (8). However, LEER is a highly skilled surgery that can only be done by a proficient surgeon. It requires definite anatomical knowledge of pelvic sidewall structure due to the risk of massive bleeding during resection of tumors invading the major pelvic vessels, and adhesion and fibrosis in a previously debulked or irradiated pelvis can increase surgical morbidity and mortality (9, 10).

Despite these limitations, LEER reportedly produces a five-year survival rate of about 50%, and the number of studies on the feasibility of LEER for selected patients with PSRCC has gradually been increasing since 2015 (6, 9–14). However, the criteria for identification of patients for whom LEER may be beneficial remain ambiguous, and there is no evidence as to whether LEER may be more effective than palliative chemo or targeted therapy alone. This is an especially important question considering the high number of morbidities related to LEER. Thus, we performed a prospective cohort study to evaluate the efficacy and safety of LEER for patients with PSRCC and investigated the criteria for selection of patients who may benefit from LEER compared to chemo or targeted therapy alone.

**MATERIALS AND METHODS**

**Study Design**

We prospectively collected data on patients with PSRCC who underwent LEER in Seoul National University Hospital between December 2016 and December 2019. The study protocol was registered on ClinicalTrials.gov (NCT02986568) before any patients. For the prospective cohort study, we consecutively recruited patients who were aged 20 years or older; had Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; had recurrent or refractory cervical cancer; had unilateral PSRCC not involving the greater sciatic foramen with or without uncontrolled pelvic pain despite sufficient opioid usage; had PSRCC that might be cured or uncontrolled pelvic pain that might be relieved by LEER; signed the approved informed consent form; and had no other treatment options except for LEER. We excluded patients who were under 20 years of age; had ECOG performance status of 2 or more; had bilateral PSRCC; had a treatment option other than LEER; or refused to sign the approved informed consent form.

As historical controls, we retrospectively collected data on patients with PSRCC who received chemo or targeted therapy alone without LEER between January 2000 and December 2019. The inclusion and exclusion criteria for the retrospective group were the same as those for the prospective group except that informed consent was not necessary. For both cohorts, we collected data such as patient age; histologic type; size of pelvic sidewall tumors on imaging studies; disease extent according to TNM stage on radiologic imaging studies (15); topographic location and direction of pelvic sidewall tumors; types of prior treatment; tumor response to prior treatment; prior treatment-free interval (PTFI), defined as the time from completion of prior treatment to disease progression necessitating the current treatment; the current treatment line for PSRCC; regimen types and cycles of chemo or targeted therapy for the current treatment; and the duration of follow-up.

** Procedures**

In the prospective cohort, LEER was performed according to the surgical procedures detailed in previous reports (7, 9). In brief, a midline incision was made on the abdomen, the bilateral paracolic gutters were incised, and the peritoneum was dissected at the base of the radix mesent erii for bowel mobilization. Then, the bilateral ureters were identified and liberated. If pelvic sidewall tumors had invaded the bladder...
and rectum, the bilateral paravesical and pararectal spaces and the space of Retzius were developed. The bilateral ureters were cut as close to the bladder as possible and the negative margins of the distal ureters were identified by frozen sections. Moreover, the mesosigmoid or mesorectum was skeletonized, and the blood vessels therein were ligated at a sufficient distance from the tumor. Bowel continuity was interrupted using a gastrointestinal anastomosis (GIA) staplers at the level of the proximal margin with no gross tumor.

For en bloc resection of pelvic sidewall tumors with negative resection margins, we first ligated the internal iliac artery just below the bifurcation of the common iliac artery and then divided the internal iliac vein at the bifurcation. The branches of the posterior division of the internal iliac vessel system, including the superior gluteal, inferior gluteal, and internal pudendal arteries and veins were transected using hemoclips or hemolock clips. Depending on the topography of PSRCC, the obturator internus muscle, the coccygeus muscle, and the levator ani muscles such as the pubococcygeus and iliococcygeus muscles were incised and separated from the pelvic sidewall with a Cobb periosteal dissector. Thereafter, the vulva was incised for removal of the urethra, lower vagina, and anus, and a dissection was carried to enter the space of Retzius and divide the pelvic floor musculature laterally and posteriorly. Recurrent pelvic sidewall tumors that were surrounded by the pelvic organs and adjacent pelvic floor muscles were removed through the inferior pelvic opening. After LEER, permanent colostomy and ileal conduit urinary diversion were carried out. In some cases, depending on the tumor location, the bladder, vagina and rectum could be preserved after checking the negative resection margin in frozen sections.

R0 resection was defined as lack of tumor invasion in the tissues of the lateral margins of the obturator internus, coccygeus, iliococcygeus and pubococcygeus muscles and the internal iliac vessel system ipsilateral to pelvic sidewall tumors on pathologic examination. If the bladder or rectum was preserved, an absence of tumor invasion in tissues surrounding the removed lesions according to multiple biopsies was considered R0 resection.

Postoperative complications were assessed by the Memorial Sloan Kettering Cancer Center criteria (16). For chemo or targeted therapy, single or combination regimens were used in both the prospective and retrospective cohorts. Moreover, targeted therapy using paclitaxel, cisplatin, and bevacizumab based on the Gynecologic Oncology Group (GOG) 240 trial was used beginning in August 2015 due to changes in insurance coverage (17, 18).

**FIGURE 1** Diagram of the study flow.
Outcomes

The primary outcomes were the differences in treatment-free interval (TFI), progression-free survival (PFS), treatment-free survival (TFS), and overall survival (OS) between the prospective and retrospective cohorts. TFI was defined as the time interval from completion of treatment for PSRCC to disease progression; PFS was defined as the time interval from the start of treatment for PSRCC to disease progression; TFS was defined as the time interval from the start of treatment for PSRCC to cancer-related death or the end of the study; and OS was defined as the time interval from the diagnosis of cervical cancer to cancer-related death or the end of the study.

The secondary outcomes were the differences in tumor response, neurologic disturbance of the lower extremities, and severity of pelvic pain between the two groups. We assessed tumor response using the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (19), and neurologic tumor response representing the total amount of various opioids prescribed to control pelvic pain (20).

Statistical Analysis

We compared non-parametric variables between the two groups with Mann-Whitney U, chi-square, and Fisher’s exact tests. Moreover, we compared TFI, PFS, TRS, and OS between the two groups by Kaplan-Meier survival analysis with the log-rank test. Statistical tests were two-sided, and P < 0.05 was considered statistically significant. SPSS software version 21.0 (SPSS Inc., Chicago, IL, USA) was used.

RESULTS

Study Population

Among 1,295 patients with cervical cancer, 443 (34.2%) showed disease recurrence. Of patients with disease recurrence, we excluded those with distant metastasis alone (n = 237, 18.3%), central recurrence alone (n = 60, 4.6%), and central recurrence and distant metastasis (n = 7, 0.5%); also, 59 (4.6%) were lost to follow-up. Among the remaining 80 patients with PSRCC (6.2%), we also excluded 12 (0.9%), six (0.5%), and three patients (0.2%) due to an ECOG performance status of two or more, denial of further treatment, and invasion of the greater sciatic foramen, respectively. Finally, we included 28 (2.2%) and 31 (2.4%) patients in the prospective and retrospective cohorts, respectively (Figure 1).

Table 1 shows the clinico-pathologic characteristics of the study subjects. There were no differences in age, histologic types, severity of muscle weakness and neuralgia in the lower limbs according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Moreover, pelvic pain severity was evaluated using both a numerical rating scale (NRS) and the number of morphine milligram equivalents (MME), representing the total amount of various opioids prescribed to control pelvic pain (20).

| Characteristics | Prospective cohort (n=28) | Retrospective cohort (n=31) | P value |
|-----------------|--------------------------|----------------------------|---------|
| Age (years)     | 44.5 (28-70)             | 47 (31-71)                 | 0.76    |
| Histological types | 0.47                     |                            |         |
| Squamous cell carcinoma | 21 (75)                  | 26 (83.9)                  |         |
| Endocervical adenocarcinoma | 3 (10.7)               | 4 (12.9)                   |         |
| Mucinous adenocarcinoma  | 2 (7.1)                  | 0 (0)                      |         |
| Adenosquamous carcinoma | 1 (3.6)                  | 1 (3.2)                    |         |
| Large cell neuroendocrine tumor | 1 (3.6)               | 0 (0)                      |         |
| FIGO stage      |                          |                            | 0.829   |
| Stage I         | 15 (53.6)                | 14 (45.2)                  |         |
| Stage II        | 7 (25)                   | 7 (22.6)                   |         |
| Stage III       | 3 (10.7)                 | 5 (16.1)                   |         |
| Stage IV        | 3 (10.7)                 | 5 (16.1)                   |         |
| Size of pelvic sidewall tumor on imaging studies (cm) | 3.5 (1.7-7.7) | 3.6 (1-9.7) | 0.83 |
| Radiologic TNM stage |                        |                            |         |
| T - Tumor       |                          |                            | 0.24    |
| rT3b            | 23 (82.1)                | 29 (93.5)                  |         |
| rT4             | 5 (17.9)                 | 2 (6.5)                    |         |
| N - Regional lymph nodes |              |                            | 0.46    |
| rN0             | 18 (64.3)                | 17 (54.8)                  |         |
| rN1             | 10 (35.7)                | 14 (45.2)                  |         |
| M - Distant metastasis |                      |                            | 0.54    |
| rM0             | 21 (75)                  | 21 (67.7)                  |         |
| rM1             | 7 (25)                   | 19 (62.9)                  |         |
| Topographic location of pelvic sidewall tumor |              |                            | 0.27    |
| Infra-iliac ischiopubic | 2 (7.1)                  | 0 (0)                      |         |
| Infra-iliac acetabular | 14 (50)                  | 23 (74.2)                  |         |
| Peri-iliac acetabular | 2 (7.1)                  | 2 (6.5)                    |         |
| Infra-iliac sacrococcygeal | 9 (32.1)                | 5 (16.1)                   |         |
| Peri-iliac iliosacral | 1 (3.6)                  | 1 (3.2)                    |         |
| Direction of pelvic sidewall tumor |              |                            | 0.42    |
| Right           | 15 (53.6)                | 14 (45.2)                  |         |
| Left            | 13 (46.4)                | 17 (54.8)                  |         |
| Types of prior treatment |                      |                            | 0.83    |
| CCRT            | 3 (10.7)                 | 0 (0)                      |         |
| Surgery and chemoradiation | 5 (17.9)                | 7 (22.6)                   |         |
| Chemoradiation and chemotherapy | 3 (10.7)               | 10 (32.3)                  |         |
| Surgery, chemoradiation and chemotherapy | 17 (60.7)              | 14 (45.2)                  |         |
| Tumor response to prior treatment |              |                            | 0.89    |
| Complete response | 10 (47.6)                | 3 (42.9)                   |         |
| Partial response | 4 (19)                   | 1 (14.3)                   |         |
| Progressive disease | 7 (33.3)                 | 5 (32.3)                   |         |
| Prior treatment-free interval | 9.3 (0.5, 321.5)       | 7.5 (0.6, 158.5)           | 0.89    |
| 2(months)       |                          |                            |         |
| Current treatment line for pelvic sidewall tumor |              |                            | 0.01    |
| 1               | 21 (75)                  | 31 (100)                   |         |
| 2               | 5 (17.9)                 | 0 (0)                      |         |
| 3               | 2 (7.1)                  | 0 (0)                      |         |
| Use of bevacizumab | 0.02                     |                            |         |
| No              | 14 (50)                  | 25 (80.6)                  |         |
| Before the current treatment | 12 (42.9)               | 2 (6.5)                    |         |
| During the current treatment | 2 (7.1)                 | 3 (9.7)                    |         |
| After the current treatment | 0 (0)                   | 1 (3.2)                    |         |
| Duration of follow-up (months) | 36.7 (14.5-331.7)       | 35.7 (9.4-196.2)           | 0.51    |

Data are median (range) or n (%). Patients in the prospective cohort received laterally extended endopelvic resection followed by chemo or targeted therapy, whereas those in the retrospective cohort received chemo or targeted therapy alone for pelvic sidewall recurrence of cervical cancer.
size of pelvic sidewall tumors on imaging studies, radiologic TNM stage, topographic location and direction of pelvic sidewall tumors, types of prior treatment, tumor response to prior treatment, PTFI, or duration of follow-up between the two groups. In the prospective cohort, only 21 patients (75%) received LEER immediately after being diagnosed with PSRCC, whereas seven (25%) received second- or third-line chemo or targeted therapy prior to LEER. After LEER, three patients (10.7%) did not receive chemo or targeted therapy due to renal failure (n = 1) and rapid disease progression during management of postoperative complications (n = 2). Although there was no difference in the types of treatment regimens between the two groups, combination therapy using paclitaxel, cisplatin and bevacizumab was more common in the prospective cohort than in the retrospective cohort, and more cycles of chemo or targeted therapy were administered in the prospective cohort (Table 2).

**Treatment Outcomes**

In terms of surgical extents, we were able to preserve the rectum alone and both the rectum and bladder in ten (35.7%) and three patients (10.7%), respectively. Among the pelvic sidewall structures, the obturator internus, pubococcygeus, iliococcygeus, and coccygeus muscles were resected in nine (32.1%), 12 (42.9%), 16 (57.1%), and 15 patients (53.6%), respectively, and the internal iliac vessel system was removed in 27 patients (96.4%; Table 3).

With regard to pathologic outcomes related to LEER, the median value of the size of pelvic sidewall tumors was 4.6 cm, and we achieved R0 resection in 26 patients (92.9%). Among the pelvic sidewall structures, tumor involvement in the obturator internus, pubococcygeus, iliococcygeus, and coccygeus muscles was seen in five (17.9%), four (14.3%), six (21.4%), and four (14.3%) patients, respectively, and 14 (50%) patients (10.7%) did not receive chemo or targeted therapy due to renal failure (n = 1) and rapid disease progression during management of postoperative complications (n = 2).

**Table 2 | Regimen type and number of cycles of chemo or targeted therapy for the current treatment.**

| Regimen Type                      | Prospective cohort (n = 28) | Retrospective cohort (n = 31) | P value |
|-----------------------------------|-----------------------------|------------------------------|---------|
| No                                | 3 (10.7)                    | 0 (0)                        | 0.13    |
| Paclitaxel/carboplatin            | 3 (10.7)                    | 12 (38.7)                    |         |
| Paclitaxel/cisplatin              | 2 (7.1)                     | 0 (0)                        |         |
| Topotecan/cisplatin               | 9 (32.1)                    | 8 (25)                       |         |
| 5-fluorouracil/cisplatin          | 2 (7.1)                     | 2 (6.5)                      |         |
| 5-fluorouracil/carboplatin        | 1 (3.6)                     | 1 (3.2)                      |         |
| Gemcitabine                       | 4 (14.3)                    | 1 (3.2)                      |         |
| Cisplatin                         | 1 (3.6)                     | 2 (6.5)                      |         |
| Topotecan                         | 1 (3.6)                     | 0 (0)                        |         |
| Etoposide                         | 0 (0)                       | 1 (3.2)                      |         |
| Irinotecan                        | 0 (0)                       | 1 (3.2)                      |         |
| Paclitaxel/cisplatin/bevacizum    | 2 (7.1)                     | 3 (9.7)                      |         |
| Cycles                            | 3.5 (2 - 6)                 | 5 (3 - 15)                   | <0.03   |

Data are median (range) or n (%).

**Table 3 | Surgical extent.**

| Surgical Extent | Prospective cohort (n = 28) |
|-----------------|-----------------------------|
| Preservation of the pelvic organs | No 15 (53.6) |
| Rectum alone    | 10 (35.7) |
| Bladder and rectum alone | 3 (10.7) |
| Extent of resection | |
| Bladder and urethra | 25 (89.3) |
| Rectum and anus  | 15 (53.6) |
| Uterus           | 18 (64.3) |
| Vagina           | 20 (71.4) |
| Perineum         | 15 (53.6) |
| Obturator internus muscle | 9 (32.1) |
| Pubococcygeus muscle | 12 (42.9) |
| Iliococcygeus muscle | 16 (57.1) |
| Coccygeus muscle | 15 (53.6) |
| Internal iliac vessel system | 27 (96.4) |
| Estimated blood loss (ml) | 1800 (400 - 16800) |
| Transfusion      | 4 (0 - 39) |
| Operation time (minutes) | 465 (190 - 760) |
| Hospitalization (days) | 22 (8 - 86) |

Data are median (range) or n (%).

**Table 4 | Pathologic outcomes.**

| Pathologic Outcome | Prospective cohort (n = 28) |
|--------------------|-----------------------------|
| Size of pelvic sidewall tumors (cm) | 4.6 (1 - 11) |
| Resection margin   | R0 26 (92.9) |
|                    | R1 2 (7.1) |
| Extent of tumor involvement | |
| Bladder            | 17 (60.7) |
| Urethra            | 3 (10.7) |
| Rectum             | 11 (39.3) |
| Anus               | 7 (25) |
| Uterus             | 1 (3.6) |
| Vagina             | 16 (57.1) |
| Perineum           | 0 (0) |
| Obturator internus muscle | 5 (17.9) |
| Pubococcygeus muscle | 4 (14.3) |
| Iliococcygeus muscle | 6 (21.4) |
| Coccygeus muscle   | 4 (14.3) |
| Internal iliac vessel system | 14 (50) |

Data are median (range) or n (%).

showed tumor involvement in the internal iliac vessel system (Table 4).

Postoperative complications developed in 17 patients (60.7%) after LEER. Arterial or venous thrombus was the most common complication (14.2%). Moreover, grade 3 or 4 complications according to the MSKCC surgical secondary events grading system were observed in 14 patients (50%; Table 5). In the retrospective cohort, the recto-vaginal fistula developed in 5 patients (16.1%); of these, four patients (12.9%) received bevacizumab. The association between bevacizumab usage and fistula development was not statistically significant (p = 0.088).

**Table 5 | Pathologic outcomes.**

| Pathologic Outcome | Prospective cohort (n = 28) |
|--------------------|-----------------------------|
| Hospitalization (days) | 22 (8 - 86) |

Data are median (range) or n (%).

Patients in the prospective cohort received laterally extended endopelvic resection followed by chemo or targeted therapy.
Survival analysis between the two groups revealed no differences in TFI, PFS, TRS, and OS between the prospective and retrospective cohorts in all patients (Figure 2). To go into greater detail, we also performed subgroup analyses based on the following favorable indications according to previous reports: tumor size ≤ 5 cm; PFTI > 5 months; and no distant metastasis (8, 21). As a result, we also found no difference in TFI, PFS, TRS, and OS between the prospective and retrospective cohorts based on the favorable indications (Figure 3). Furthermore, we conducted subgroup analyses based on the median value of PFTI, 9.2 months. In the 30 patients with PFTI ≥ 9.2 months, there were no differences in TFI, PFS, TRS and OS between the two groups, whereas LEER followed by chemo or targeted therapy was associated with improved TFI, PFS, and OS compared to chemo or targeted therapy alone (median values, 2.8 vs. 0.9 months; 7.4 vs. 4.1 months; 30.1 vs. 16.9 months; P ≤ 0.05) in the 29 patients with PFTI < 9.2 months (Figure 4).

Next, we conducted univariate and multivariate analyses to identify factors affecting survival (Supplementary Tables 1–3).

### TABLE 5 | Postoperative complications.

| Type                     | Prospective cohort (n = 28) |
|--------------------------|----------------------------|
|                         | No                         | 11 (39.3) |
| Arterial or venous thrombus | 4 (14.2)               |
| Leakage from the anastomotic site | 3 (10.7)           |
| Infected lymphoceles     | 2 (7.1)                   |
| Acute pyelonephritis    | 1 (3.6)                   |
| Hydronephrosis           | 1 (3.6)                   |
| Ileus                    | 1 (3.6)                   |
| Renal stone              | 1 (3.6)                   |
| Paralysis of low extremity | 1 (3.6)              |
| Wound dehiscence         | 1 (3.6)                   |
| Grade                    |                           |
| 0                        | 11 (39.3)                 |
| 2                        | 3 (10.7)                  |
| 3                        | 12 (42.9)                 |
| 4                        | 2 (7.1)                   |

Data are median (range) or n (%). Patients in the prospective cohort received laterally extended endopelvic resection followed by chemo or targeted therapy.

**FIGURE 2** | Comparison of treatment-free interval, progression-free survival, treatment-related survival and overall survival between the prospective and retrospective cohorts in all patients.
The results showed that PTFI ≥ 9.2 months and LEER followed by chemo or targeted therapy were associated with improved TFI, PFS, TRS, and OS in all patients. Moreover, first-line treatment for PSRCC improved TFI and TRS, and rT3b was related to better TRS and OS. However, previous use of bevacizumab was related to worse TRS. In the subgroup analyses based on median PTFI, rT3b and current use of bevacizumab were factors associated with improved TFI, PFS, TSR, and OS in the 30 patients with PTFI ≥ 9.2 months. Furthermore, first-line treatment for PSRCC improved TRS and OS, and squamous cell carcinoma was associated with better OS. Although LEER was related to better TRS, previous use of bevacizumab was associated with reduced TRS. In the 29 patients with PTFI < 9.2 months, LEER was associated with improved TFI, PFS, TRS, and OS. Moreover, first-line treatment for PSRCC was associated with improved TFI and tumor size < 4.2 cm on imaging studies was related to better TRS and OS (Table 6).
In terms of tumor response, complete response was more common in the prospective cohort than in the retrospective cohort (55.6% vs. 19.4%; P < 0.01). Despite the lack of differences in disease recurrence and death between the two groups, the prospective cohort showed a lower rate of PSRCC (25% vs. 67.7%; P = 0.01) and a higher rate of distant metastasis (53.6% vs. 6.5%; P = 0.01) than the retrospective cohort. Although the incidence of muscle weakness after treatment did not differ between the two groups, neuralgia was more common in the prospective cohort than in the retrospective cohort (50% vs. 12.9%; P < 0.01). However, there was no difference in grade 3 neuralgia between the two groups (3.6% vs. 0%; P = 0.48). Regarding pelvic pain severity, the lowest and highest NRS did not differ before and after treatment between the two groups. Although there was also no difference in the MME required to control pelvic pain before treatment between the two groups, the MME required to control pelvic pain severity, ...
Given these treatment options, the rates of pain after treatment was less in the prospective cohort than in the retrospective cohort (median, 0 vs. 15; P < 0.01; Table 7).

**DISCUSSION**

LEER has long been used to remove pelvic tumors within ontogenetic cancer fields and sustain loco-regional tumor control (22–24). LEER is done by resecting the pelvic floor and sidewall muscles and the internal iliac vessel system surrounding pelvic sidewall tumors. R0 resection is more common in patients with relapsed pelvic malignancies (25). Although a previous study showed that the five-year OS and PFS rates were 46% and 35%, respectively, in patients with PSRCC without a therapeutic alternative to LEER (8), the current study demonstrated that the prognosis for such patients is relatively poor, with a two-year PFS rate of 16.3% and a similar five-year OS rate of 33.9%. This poor PFS after LEER is most likely because ten patients (35.7%) with regional lymph node metastasis and seven (25%) with distant metastasis were included in the prospective cohort. By contrast, in the previous study, only 22.2% of patients had regional lymph node metastasis without distant metastasis.

Furthermore, the favorable indications for LEER (tumor size ≤5 cm; PFTI >5 months; no distant metastasis) were not related to improved survival, and the prognosis of patients with these indications remained relatively poor, with a two-year PFS rate of 23.1% despite a similar OS rate of 42.1%. This poor prognosis may be related to the high potential for distant metastasis seen in PSRCC. Although pelvic sidewall tumors can infiltrate the remaining lymphatic vessels connected to lymph node basins in the pelvic visceroperiportal compartments (27, 28), complete resection of these compartments outside the scope of LEER is difficult because of severe fibrosis or adhesion due to previous surgery or radiotherapy, which can cause distant metastasis if tumor cells are present in these compartments.

**TABLE 6 | Factors affecting survival.**

| Factor                                      | All (n = 59) | PFTI ≥ 9.2 months (n = 30) | PFTI < 9.2 months (n = 29) |
|---------------------------------------------|-------------|----------------------------|----------------------------|
| Treatment-free interval                     | –           | –                          | –                          |
| rT3b                                        | –           | 0.04 (0.01 - 0.57)          | –                          |
| PFTI ≥ 9.2 months                           | 0.42 (0.23 - 0.78) | –                          | –                          |
| First-line treatment for PSRCC              | 0.28 (0.09 - 0.80) | –                          | 0.18 (0.03 - 0.98)          |
| Use of bevacizumab                          | Current     | 0.13 (0.02 - 0.65)          | –                          |
| LEER followed by chemo or targeted therapy  | 0.54 (0.28 - 0.98) | –                          | 0.28 (0.12 - 0.68)          |
| Progression-free survival                   | Current     | 0.18 (0.03 - 0.97)          | –                          |
| PFTI ≥ 9.2 months                           | 0.47 (0.26 - 0.85) | –                          | –                          |
| Use of bevacizumab                          | Current     | 0.26 (0.06 - 0.82)          | –                          |
| LEER followed by chemo or targeted therapy  | 0.60 (0.33 - 0.83) | –                          | 0.27 (0.11 - 0.66)          |
| Treatment-related survival                  | Current     | 0.39 (0.17 - 0.96)          | –                          |
| Tumor size < 4.2 cm on imaging studies      | 0.41 (0.08 - 0.57) | 0.03 (0.02 - 0.58)          | –                          |
| rT3b                                        | PFTI ≥ 9.2 months | 0.51 (0.27 - 0.98)          | –                          |
| First-line treatment for PSRCC              | 0.29 (0.10 - 0.88) | 0.10 (0.01 - 0.76)          | –                          |
| Use of bevacizumab                          | Previous    | 5.48 (1.12 - 34.01)         | –                          |
| Tumor size < 4.2 cm on imaging studies      | Current     | 0.02 (0.01 - 0.36)          | –                          |
| Overall survival                            | LEER followed by chemo or targeted therapy | 0.44 (0.18 - 0.83)          | –                          |
| Squamous cell carcinoma                     | Current     | 0.09 (0.01 - 0.58)          | –                          |
| Tumor size < 4.2 cm on imaging studies      | 0.38 (0.16 - 0.89)          | –                          |
| rT3b                                        | 0.24 (0.09 - 0.61) | 0.23 (0.01 - 0.32)          | –                          |
| PFTI ≥ 9.2 months                           | 0.28 (0.14 - 0.55) | 0.06 (0.01 - 0.69)          | –                          |
| First-line treatment for PSRCC              | –           | 0.12 (0.02-0.79)            | –                          |
| Use of bevacizumab                          | LEER followed by chemo or targeted therapy | 0.50 (0.09 - 0.61)          | 0.37 (0.15 - 0.88)          |

Data are adjusted hazard ratio (95% confidence interval).

LEER, laterally extended endopelvic resection; PSRCC, pelvic sidewall recurrence of cervical cancer; PFTI, prior treatment-free interval.
TABLE 7 | Treatment outcomes.

| Characteristics                      | Prospective cohort (n = 28) | Retrospective cohort (n = 31) | P value |
|--------------------------------------|----------------------------|-------------------------------|---------|
| Tumor response                       |                            |                               | <0.01   |
| Complete response                    | 15 (55.6)                  | 6 (19.4)                      |         |
| Partial response                     | 0 (9)                      | 4 (12.9)                      |         |
| Progressive disease                  | 12 (44.4)                  | 21 (67.7)                     | 0.46    |
| Disease recurrence                   | 23 (82.1)                  | 28 (90.3)                     | 0.01    |
| Recurrent sites                      |                            |                               |         |
| Central                              | 1 (3.6)                    | 4 (12.9)                      |         |
| Pelvic sidewall                      | 7 (25)                     | 21 (67.7)                     |         |
| Ipsilateral                          | 6 (21.4)                   | 21 (67.7)                     |         |
| Contralateral                        | 1 (3.6)                    | 0 (0)                         |         |
| Distant                              | 15 (53.6)                  | 2 (6.5)                       |         |
| Death                                | 18 (64.3)                  | 26 (83.9)                     | 0.08    |
| Neurologic disturbance of low extremity |                          |                               | 0.06    |
| Muscle weakness                      |                            |                               |         |
| No                                   | 22 (78.6)                  | 31 (100)                      |         |
| Grade 1                              | 1 (3.6)                    | 0 (0)                         |         |
| Grade 2                              | 2 (7.1)                    | 0 (0)                         |         |
| Grade 3                              | 3 (10.7)                   | 0 (0)                         |         |
| Neuralgia                            |                            |                               | 0.01    |
| No                                   | 14 (50)                    | 27 (87.1)                     |         |
| Grade 1                              | 8 (28.6)                   | 1 (3.2)                       |         |
| Grade 2                              | 5 (17.9)                   | 3 (9.7)                       |         |
| Grade 3                              | 1 (3.8)                    | 0 (0)                         |         |
| Pelvic pain severity                 |                            |                               |         |
| Pre-treatment NRS                    |                            |                               |         |
| Lowest                               | 2 (0 - 4)                  | 2 (0 - 5)                     | 0.86    |
| Highest                              | 3 (0 - 9)                  | 3 (0 - 10)                    | 0.90    |
| Post-treatment NRS                   |                            |                               |         |
| Lowest                               | 0 (0 - 4)                  | 0 (0 - 5)                     | 0.35    |
| Highest                              | 3 (0 - 6)                  | 3 (0 - 9)                     | 0.37    |
| Pre-treatment MME/day                | 0 (0 - 312)                | 0 (0 - 210)                   | 0.40    |
| Post-treatment MME/day               | 0 (0 - 60)                 | 15 (0 – 219)                  | <0.01   |

Data are median (range) or n (%).
Patients in the prospective cohort received laterally extended endopelvic resection followed by chemo or targeted therapy, while those in the retrospective cohort received chemo or targeted therapy alone for pelvic sidewall recurrence of cervical cancer. MME, morphine milligrams equivalents; NRS, numeral rating scale.

The above explanation is supported by the finding that PSRCC was associated with a similar prognosis as distant metastasis in a previous study (4), and distant metastasis was found in 25% of patients with PSRCC in this study. On the other hand, if LEER was improperly implemented in this study, its use may be related to poor prognosis. However, the finding that 53.6% of patients with relapse after LEER showed distant metastasis supports the surgical suitability of LEER with appropriate loco-regional control.

The most important finding of this study is that LEER may be beneficial for the treatment of PSRCC in patients with PTFI <9.2 months. Patients with PTFI ≥9.2 months may have platinum sensitivity (29–31), which can increase tumor response to chemotherapy such that it matches the surgical effect of LEER. Since this study showed that targeted therapy using bevacizumab increased survival, as in the GOG 240 trial (18), combined chemotherapy with bevacizumab can be considered as a first-line treatment for PSRCC because its use avoids surgical complications and its efficacy is similar to that of LEER in patients with PTFI ≥ 9.2 months.

Importantly, LEER may be effective at reducing the MME required to control pelvic pain. Although opioid-based analgesic treatment can relieve pelvic pain in more than 70% of patients, many patients still suffer due to underutilization of opioids and the adverse effects of opioids (32). Since sciatica occurs when one or more nerve roots from L4 to S3 are compressed by pelvic sidewall tumors, tumor removal through LEER can relieve the pressure on nerve roots and markedly reduce the associated pain (33), which means that LEER can be considered as a palliative surgery for relief of uncontrolled sciatica caused by PSRCC (12).

This study has some limitations. First, the small number of enrolled patients and the heterogeneity of both cohorts due to the rarity of PSRCC may have introduced bias. Second, little relevant data was available with which to design this study and to calculate the appropriate sample size. Third, only the combination therapy using paclitaxel, cisplatin, and bevacizumab has been approved for recurrent cervical cancer since March 2015, whereas the use of bevacizumab monotherapy is not currently approved in our country. Thus, the rate of bevacizumab usage was low this study. Fourth, the comparison of pain severity should be interpreted carefully, considering the two different study designs. Fifth, we did not include bilateral pelvic sidewall recurrence, because bilateral LEER is insufficiently safe. Thus, it is essential to more clearly evaluate the efficacy and safety of LEER compared to chemo or targeted therapy alone through a multicenter study based on our results.

To the best of our knowledge, this is the first comparative study between LEER and chemo or targeted therapy alone for PSRCC. Compared to chemo or targeted therapy alone, LEER may improve survival, with increased tumor response in patients with PSRCC and PTFI < 9.2 months. Moreover, LEER may be an effective means of controlling the pelvic pain caused by PSRCC.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Seoul National University Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

SP: methodology, validation, formal analysis, investigation, data curation, writing-original draft, and visualization. JM: validation, investigation, and writing-review & editing.
SL: validation, investigation, and writing-review & editing. YL: validation, investigation, and writing-review & editing. HC: methodology, validation, investigation, and supervision. J-WK: methodology, investigation, and writing-review & editing. NP: methodology, validation, investigation, and supervision. HK: conceptualization, methodology, formal analysis, resources, writing - review & editing, supervision, project administration, and funding acquisition. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was supported by grants from Seoul National University (No. 800-20200458; 800-20200309; 800-20190437).

**ACKNOWLEDGMENTS**

We thank Seung Bum Ryoo and Ji Won Park (Department of Surgery), Jong Hwa Seo (Department of Anesthesiology and Pain Medicine), Sang Youn Kim (Department of Radiology) and Chang Wook Jeong (Department of Urology), as well as other members of the FUSION Study Group at Seoul National University Hospital, for taking part in the collaborative work on LEER. Moreover, we deeply appreciate Tae Hun Kim (Seoul Metropolitan Government Seoul National University Boramae Medical Center), Kyung Jin Min (Korea University Medical Center), Seung-Hyuk Sim (Konkuk University Medical Center), Myong Cheol Lim (National Cancer Center), Sung Jong Lee (Seoul St. Mary’s Hospital) and Suk Joon Chang (Ajou University School of Medicine) who participated in a panel during a live LEER surgery performed by HSK at the 2018 Highlighted Access on Disease Recurrence Of Cervical Cancer (HADROC) symposium at Seoul National University Hospital on August 18, 2018.

**REFERENCES**

1. Vizzielli G, Tortorella L, Conte C, Chiantera V, Gallotta V, Foschi N, et al. Is a Vaginectomy Enough or Is a Pelvic Exenteration Always Required for Surgical Treatment of Recurrent Cervical Cancer? A Propensity-Matched Study. *Ann Surg Oncol* (2020) 28(6):3281–90. doi: 10.1245/s10434-020-09207-w
2. Panici PB, Manci N, Bellati F, Di Donato V, Marchetti C, De Falco C, et al. Vaginectomy: A Minimally Invasive Treatment for Cervical Cancer Vaginal Recurrence. *Int J Gynecol Cancer* (2009) 19(9):1625–31. doi: 10.1111/ IGCG.0b013e3181a80fa
3. Backes FJ, Billingsley CC, Martin DD, Tierney BJ, Eisenhauer EL, Cohn DE, et al. Does Intra-Operative Radiation at the Time of Pelvic Exenteration Improve Survival for Patients With Recurrent, Previously Irradiated Cervical, Vaginal, or Vulvar Cancer? *Gynecol Oncol* (2014) 135(1):95–9. doi: 10.1016/j.ygyno.2014.07.093
4. Kim TH, Kim MH, Kim BJ, Park SI, Ryu SY, Cho CK. Prognostic Importance of the Site of Recurrence in Patients With Metastatic Recurrent Cervical Cancer. *Int J Radiat Oncol Biol Phys* (2017) 98(5):1124–31. doi: 10.1016/j.ijrob.2017.03.029
5. Höckel M, Dornhöfer N. Pelvic Exenteration for Gynaecological Tumours: Achievements and Unanswered Questions. *Lancet Oncol* (2006) 7(10):837–47. doi: 10.1016/s1470-2045(06)70903-2
6. Solomon MJ, Brown KG, Koh CE, Lee P, Austin KK, Masya L. Lateral Pelvic Compartment Excision During Pelvic Exenteration. *Br J Surg* (2015) 102(13):1710–7. doi: 10.1002/bjs.9915
7. Höckel M. Laterally Extended Endopelvic Resection (LEER)-Principles and Practice. *Gynecol Oncol* (2008) 111(2 Suppl):S13–7. doi: 10.1016/j.ygyno.2008.07.022
8. Höckel M. Laterally Extended Endopelvic Resection. Novel Surgical Treatment of Locally Recurrent Cervical Carcinoma Involving the Pelvic Side Wall. *Gynecol Oncol* (2003) 91(2):369–77. doi: 10.1016/s0090-8258(03)00502-x
9. Park SJ, Kim HS. Laterally Extended Endopelvic Resection With Nephrectomy for Vaginal Cancer. *Gynecol Oncol* (2019) 152(1):218–9. doi: 10.1016/j.ygyno.2018.11.003
10. Kanao H, Aoki Y, Hisa T, Takeshima N. Laparoscopic Laterally Extended Endopelvic Resection (LEER) For Cervical Carcinoma Recurring at the Pelvic Sidewall After Concurrent Chemoradiotherapy: Our Experience in Three Cases. *Gynecol Oncol* (2018) 149(2):428–9. doi: 10.1016/j.ygyno.2018.02.002
11. Cibula D, Mitáš P. Laterally Extended Endopelvic Resection With External Iliac Vessels Resection and Crossover Ileofemoral Bypass. *Int J Gynecol Cancer* (2019) 29(8):1338. doi: 10.11136/ijgc-2019-000461
12. Kanao H, Aoki Y, Fusegi A, Takeshima N. Should Indications for Laterally Extended Endopelvic Resection (LEER) Exclude Patients With Sciatica? *Gynecol Oncol* (2020) 31(5):e63. doi: 10.3802/jgo.2020.31.e63
13. Kanao H, Omi M, Takeshima N. Step-by-Step Demonstration of Laparoscopic Laterally Extended Endopelvic Resection for a Recurrent Endometrial Cancerous Tumor at a Sciatic Foramen, With a Detailed Explanation of the Pelvic Sidewall Anatomy. *Gynecol Oncol* (2020) 156(1):260–1. doi: 10.1016/j.ygyno.2019.11.015
14. Sozzi G, Petrillo M, Gallotta V, Di Donna MC, Ferreri M, Sambia G, et al. Laparoscopic Laterally Extended Endopelvic Resection Procedure for Gynecological Malignancies. *Int J Gynecol Cancer* (2020) 30(6):853–9. doi: 10.1136/ijgc-2019-001129
15. Bruercket JD GM, Witterkind C. TNM Classification of Malignt Tumors. 8th edition. Oxford, UK: Wiley-Blackwell (2017).
16. Strong VE, Selby LV, Soved M, Dia JH, Hoskins W, Dematteo R, et al. Development and Assessment of Memorial Sloan Kettering Cancer Center’s Surgical Secondary Events Grading System. *Ann Surg Oncol* (2015) 22(4):1061–7. doi: 10.1007/s10434-014-4141-4
17. Lee N, Kim SI, Lee M, Kim HS, Kim JW, Park NH, et al. Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer. *In Vivo* (2019) 33(3):863–8. doi: 10.21873/invivo.11551
18. Tewari KS, Sill MW, Long H3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved Survival With Bevacizumab in Advanced Cervical Cancer. *N Engl J Med* (2014) 370(8):734–43. doi: 10.1056/NEJMoa1309748
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). *Eur J Cancer* (2009) 45(2):228–47. doi: 10.1016/j.ejca.2008.10.026
20. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016. *Jama* (2016) 315(15):1624–45. doi: 10.1001/jama.2016.1646
21. Brunschwig A, Barber HR. Pelvic Exenteration Combined With Resection of Segments of Bony Pelvis. *Surgery* (1969) 65(3):417–20. doi: 10.1097/00006254-196906000-00027
22. Vizzielli G, Naik R, Dostalek L, Bizzarri N, Kucukmetin A, Tinelli G, et al. Laterally Extended Pelvic Resection for Gynaecological Malignancies: A

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.683441/full#supplementary-material
Multicentric Experience With Out-of-the-Box Surgery. *Ann Surg Oncol* (2019) 26(2):523–30. doi: 10.1245/s10434-018-6708-8

23. Vizzielli G, Chiantera V, Timelli G, Fagotti A, Gallotta V, Di Giorgio A, et al. Out-of-the-Box Pelvic Surgery Including Iliopsoas Resection for Recurrent Gynecological Malignancies: Does That Make Sense? A Single-Institution Case-Series. *Eur J Surg Oncol* (2017) 43(4):710–6. doi: 10.1016/j.ejso.2016.10.028

24. Höckel M, Dornhofer N. The Hydra Phenomenon of Cancer: Why Tumors Recur Locally After Microscopically Complete Resection. *Cancer Res* (2005) 65(8):2997–3002. doi: 10.1158/0008-5472.can-04-368

25. Höckel M. Long-Term Experience With (Laterally) Extended Endopelvic Resection (LEER) in Relapsed Pelvic Malignancies. *Curr Oncol Rep* (2015) 17(3):435. doi: 10.1007/s11912-014-0435-8

26. Höckel M. Laterally Extended Endopelvic Resection: Surgical Treatment of Infrailiac Pelvic Wall Recurrences of Gynecologic Malignancies. *Am J Obstet Gynecol* (1999) 180(2):306–12. doi: 10.1016/S0002-9378(99)70204-8

27. Höckel M, Horn LC, Manthey N, Braumann UD, Wolf U, Teichmann G, et al. Resection of the Embryologically Defined Uterovaginal (Müllerian) Compartment and Pelvic Control in Patients With Cervical Cancer: A Prospective Analysis. *Lancet Oncol* (2009) 10(7):683–92. doi: 10.1016/s1470-2045(09)70100-7

28. Höckel M, Horn LC, Fritsch H. Association Between the Mesenchymal Compartment of Uterovaginal Organogenesis and Local Tumour Spread in Stage IB-IIA Cervical Carcinoma: A Prospective Study. *Lancet Oncol* (2005) 6(10):751–6. doi: 10.1016/s1470-2045(05)70324-7

29. de Foucher T, Hennebert C, Dabi Y, Ouldamer L, Lavoué V, Dion L, et al. Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study From the FRANCOGYN Group. *J Clin Med* (2020) 9(11):3646. doi: 10.3390/jcm9113646

30. Matoda M, Tanigawa T, Omatsu K, Ushioda N, Yamamoto A, Okamoto S, et al. Platinum-Free Interval in Second-Line Chemotherapy for Recurrent Cervical Cancer. *Int J Gynecol Cancer* (2013) 23(9):1670–4. doi: 10.1097/IGC.0b013e3182a80a07

31. Takekuma M, Kuij S, Tanaka A, Takahashi N, Abe M, Hirashima Y. Platinum Sensitivity and non-Cross-Resistance of Cisplatin Analogue With Cisplatin in Recurrent Cervical Cancer. *J Gynecol Oncol* (2015) 26(3):185–92. doi: 10.3802/jgo.2015.26.3.185

32. Dreyer G, Snyman LC, Mouton A, Lindeque BG. Management of Recurrent Cervical Cancer. *Best Pract Res Clin Obstet Gynaecol* (2005) 19(4):631–44. doi: 10.1016/j.bpo.2005.03.003

33. Hopkins MP, Drescher CW, Morley GW. Claudication as a Rare Symptom of Recurrent Cervical Carcinoma. *Am Surg* (1987) 53(9):532–3.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2021 Park, Mun, Lee, Luo, Chung, Park, Song and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**